Copycat Weight-Loss Drugs Are Major Players With Consumers - KFF Health News
Source: KHN
As many as 1 in 8 American adults has tried one of the GLP-1 anti-obesity drugs, but a surprising number aren’t getting their supplies from pharma giants Novo Nordisk or Eli Lilly. Up to 30 percent of the market, by some estimates, is made up of copycat versions from compounding pharmacies. Compounding is legal, though the resulting products sometimes fall into a gray area because they’re copies of drugs under…
This is aggregated or syndicated coverage. Reporting and media belong to the original publisher.
Read the original source at KHN